BIOADAPTIVES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0005 USD | +25.00% |
|
-16.67% | 0.00% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2.985 | 2.609 | 0.4999 | 0.5081 | 0.1515 | 0.4479 |
| Enterprise Value (EV) 1 | 3.013 | 2.966 | 0.9778 | 0.8618 | 0.5181 | 0.7163 |
| P/E ratio | -1.98 x | -10.8 x | -0.58 x | -0.32 x | -0.07 x | -0.39 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 262,610,529 x | 30,618,546 x | 25,692,607 x | 8,821,961 x | 15,679,153 x |
| EV / Revenue | - | 298,550,332 x | 59,890,304 x | 43,578,226 x | 30,165,231 x | 25,075,337 x |
| EV / EBITDA | - | - | - | -1,715,748 x | -1,440,209 x | -3,568,058 x |
| EV / FCF | 5.24 x | -14.6 x | 2.25 x | -5.56 x | 3.55 x | 3.43 x |
| FCF Yield | 19.1% | -6.86% | 44.4% | -18% | 28.1% | 29.1% |
| Price to Book | -4.34 x | -3.06 x | -0.38 x | -0.46 x | -0.1 x | -0.27 x |
| Nbr of stocks (in thousands) | 18,196 | 18,829 | 20,830 | 50,810 | 252,545 | 895,750 |
| Reference price 2 | 0.1640 | 0.1386 | 0.0240 | 0.0100 | 0.000600 | 0.000500 |
| Announcement Date | 5/10/19 | 5/1/20 | 3/30/21 | 3/31/22 | 3/31/23 | 4/10/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.009934 | 0.0163 | 0.0198 | 0.0172 | 0.0286 |
| EBITDA | - | - | - | -0.5023 | -0.3598 | -0.2007 |
| EBIT 1 | -0.6579 | -0.2344 | -0.2543 | -0.6361 | -0.4219 | -0.2289 |
| Operating Margin | - | -2,359.64% | -1,557.7% | -3,216.43% | -2,456.33% | -801.4% |
| Earnings before Tax (EBT) 1 | -1.407 | -0.2389 | -0.8472 | -1.05 | -0.8956 | -0.7125 |
| Net income 1 | -1.407 | -0.2389 | -0.8472 | -1.05 | -0.8956 | -0.7125 |
| Net margin | - | -2,405.14% | -5,189.22% | -5,309.2% | -5,214.08% | -2,494.19% |
| EPS 2 | -0.0829 | -0.0128 | -0.0416 | -0.0311 | -0.008447 | -0.001274 |
| Free Cash Flow 1 | 0.5754 | -0.2035 | 0.4346 | -0.155 | 0.1458 | 0.2086 |
| FCF margin | - | -2,048.39% | 2,661.8% | -783.77% | 848.88% | 730.32% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/10/19 | 5/1/20 | 3/30/21 | 3/31/22 | 3/31/23 | 4/10/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.03 | 0.36 | 0.48 | 0.35 | 0.37 | 0.27 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.7042 x | -1.019 x | -1.337 x |
| Free Cash Flow 1 | 0.58 | -0.2 | 0.43 | -0.15 | 0.15 | 0.21 |
| ROE (net income / shareholders' equity) | 408% | 31.2% | 76.4% | 85% | 70.4% | 46% |
| ROA (Net income/ Total Assets) | -724% | -218% | -738% | -475% | -284% | -202% |
| Assets 1 | 0.1943 | 0.1095 | 0.1148 | 0.2211 | 0.3157 | 0.3518 |
| Book Value Per Share 2 | -0.0400 | -0.0500 | -0.0600 | -0.0200 | -0.0100 | -0 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 5/10/19 | 5/1/20 | 3/30/21 | 3/31/22 | 3/31/23 | 4/10/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 616K | |
| +16.80% | 8.43B | |
| +7.94% | 7.8B | |
| +15.02% | 6.82B | |
| -4.77% | 3.77B | |
| -6.75% | 3.74B | |
| +4.41% | 1.44B | |
| -30.34% | 1.06B | |
| +20.28% | 1.04B | |
| -12.85% | 890M |
- Stock Market
- Equities
- BDPT Stock
- Financials BioAdaptives, Inc.